Episode
Episode 202 - Ben Swanson - CEO of Skeletalis
- Podcast
- The BioHub - by Avetix
- Published
- Jul 16, 2026
- Duration seconds
- 2013
- Processing state
not_requested- Canonical source
- https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-202---Ben-Swanson---CEO-of-Skeletalis-e3m5k30
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-202-ben-swanson-ceo-of-skeletalis/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-202-ben-swanson-ceo-of-skeletalis.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Today we're joined by Ben Swanson , Founder and CEO of Skeletalis , a biotechnology company developing a new generation of precision medicines for bone disease. Ben's path into biotech is anything but conventional. Trained as both a dentist and a scientist, he founded Skeletalis to tackle one of the biggest unmet challenges in musculoskeletal health: how to deliver treatments directly to the parts of the skeleton that need them most, while minimizing effects on the rest of the body. At Skeletalis, Ben and his team have developed the OASIS platform —a targeted drug delivery approach designed to direct therapies to sites of active bone remodeling. Their lead focus is osteoporosis, a disease affecting hundreds of millions of people worldwide, with the potential to transform how bone diseases are treated in the future. In this conversation, we'll explore Ben's journey from academia to entrepreneurship, what it takes to build a biotech company from groundbreaking research, the future of precision medicine, and why solving bone health could have a profound impact on healthy aging